

**THE FOLLOWING DRUGS WILL BE REVIEWED AT THE
DRUG UTILIZATION REVIEW BOARD MEETING**

December 9, 2008

Georgia Department of Community Health

THERAPEUTIC CLASS	DRUG NAME	CURRENT GME PDL STATUS
Interleukin Blocker	Arcalyst*	P
Nasal Corticosteroid	Omnaris*	NP/PA
Opioid Antagonist	Relistor*	NP/PA
Serotonin Norepinephrine Reuptake Inhibitor	Pristiq*	NP/PA
Serotonin Receptor Agonist Combination	Treximet*	NP/PA
Tumor Necrosis Factor Blocker	Cimzia*	NP/PA
Supplemental Rebate Drugs Phase I		
<i>Review of new clinical product information</i>		
Beta Adrenergic Agents		
Chronic Obstructive Pulmonary Disease (COPD) Anticholinergics		
Dihydropyridine Calcium Channel Blockers/Combinations		
Lipid Lowering Agents		
Nasal Corticosteroids		
Proton Pump Inhibitors		
Serotonin Norepinephrine Reuptake Inhibitors (SNRI)		

*New drug P = Preferred NP = Non-Preferred